Skip to main content

Advertisement

SpringerLink
Log in

Meditate Temporary Implantable Nitinol Device

  • BPH-Related Voiding Dysfunction (R Lee, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

The purpose of the review was to evaluate the available literature concerning a novel minimally invasive temporary implantable nitinol device (TIND) for the treatment of benign prostatic hyperplasia (BPH), named MEDITATE (Medi-Tate®; Medi-Tate Ltd., Or Akiva, Israel).

Recent Findings

A novel technique based on an innovative device was presented being temporary implantable. Clinical experiences with MEDITATE TIND have been started. Up-to-date promising outcomes are reported.

Summary

TIND can be a viable minimally invasive surgical approach in the treatment of lower urinary tract symptoms correlated to benign prostate hyperplasia. Best candidates are patients who are unfit for major surgeries, patients who are refractory to standard medical treatment and patients who would like to preserve ejaculation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of great importance

  1. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievement and limitations. Rev Urol. 2008;10:14–25.

    PubMed  PubMed Central  Google Scholar 

  2. Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol. 2003;44:539–45.

    Article  CAS  PubMed  Google Scholar 

  3. • Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, Rwabasonga B, Risk MC, Wilt TJ. Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2017;71(4):570–81. A complete resign of the available medical treatment of BPH.

    Article  CAS  PubMed  Google Scholar 

  4. Marszalek M, Ponholzer A, Pusman M, Berger I, Madersbacher S. Transurethral resection of the prostate. Eur Urol Suppl. 2009;8:504–12.

    Article  Google Scholar 

  5. Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40.

    Article  PubMed  Google Scholar 

  6. Geavlete P. Is classical transurethral resection of the prostate, the gold standard endoscopic treatment for benign prostate hyperplasia, in real danger of being replaced? Eur Urol. 2010;58:356–9.

    Article  PubMed  Google Scholar 

  7. Lourenco T, Pickard R, Vale L, et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ. 2008;337:a1662.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gravas S, Bachmann A, Reich O, Roehrborn CG, Gilling PJ, De La Rosette J. Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int. 2011;107:1030–43.

    Article  PubMed  Google Scholar 

  9. • Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KA, Gravas S. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–109. Guidelines on current available treatments for BPH, comprehensive of the less invasive approaches.

    Article  PubMed  Google Scholar 

  10. Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2015 Apr;67(4):704–13.

    Article  PubMed  Google Scholar 

  11. Muntener M, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebel RT. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol. 2007 Aug;52(2):510–5.

    Article  PubMed  Google Scholar 

  12. Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P. Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men’s ejaculatory function: time for a bespoke approach? Int J Urol. 2016 Jan;23(1):22–35.

    Article  PubMed  Google Scholar 

  13. •• Porpiglia F, Fiori C, Bertolo R, Garrou D, Cattaneo G, Amparore D. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116(2):278–87. The only available up-to-date study published on TIND.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Regione Gonzole 10, Orbassano, 10043, Turin, Italy

    Francesco Porpiglia, Cristian Fiori, Riccardo Bertolo & Daniele Amparore

Authors
  1. Francesco Porpiglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristian Fiori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Riccardo Bertolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniele Amparore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Porpiglia.

Ethics declarations

Conflict of Interest

Drs Porpiglia, Fiori, Bertolo and Amparore declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on BPH-Related Voiding Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Porpiglia, F., Fiori, C., Bertolo, R. et al. Meditate Temporary Implantable Nitinol Device. Curr Bladder Dysfunct Rep 12, 124–128 (2017). https://doi.org/10.1007/s11884-017-0424-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-017-0424-5

Keywords

Search

Navigation